Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line

相似書籍

• Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
  由: Arrieta, Oscar, et al.
  出版: (2020)
• Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
  由: Westover, D, et al.
  出版: (2018)
• First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
  由: Nguyen, Kim-Son H, et al.
  出版: (2012)
• Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors()
  由: Nishino, Mizuki, et al.
  出版: (2012)
• Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing
  由: Jin, Ying, et al.
  出版: (2016)